Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
AMGN: second_quarter 2026 lobbying report
Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Bi
Public: Jul 20, 2026, 1:55 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
issues related to pharmaceutical drugs
Public: Jul 20, 2026, 1:43 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Public: Jul 20, 2026, 11:30 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to visas Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Public: Jul 20, 2026, 11:17 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability. Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Public: Jul 19, 2026, 3:45 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests
Public: Jul 19, 2026, 3:14 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Lobbying related to pharmaceutical policy and health care access Lobbying related to pharmaceutical policy and Medicare policy federal budget issues
Public: Jul 16, 2026, 5:24 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. 340B Program issues.
Public: Jul 16, 2026, 5:08 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to health access. PBM reform. Most Favored Nation issues. 340B Reform. Issues related to Womens Health
Public: Jul 16, 2026, 12:16 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to the pharmaceutical industry.
Public: Jul 10, 2026, 12:10 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests
Public: Jun 12, 2026, 5:07 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Educating members on issues affecting Amgen and patients
Public: Jun 12, 2026, 5:05 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: first_quarter 2026 lobbying report
Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.
Public: Jun 2, 2026, 7:20 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to drug pricing and reimbursement for prescription drugs.
Public: Jun 1, 2026, 4:00 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: 8-K company filing
Filed 8-K for an event or period dated 2026-05-19. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: Leadership change
Filed 8-K for an event or period dated 2026-05-19. Leadership change.
2 congressional households disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- USAspending
- Collection in progress76 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:27 PM EST
- Federal Register
- Stale — refresh overdue297 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable31 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:00 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST